DrugDashboards

Poly-Vent DM

Dextromethorphan HBr, Guaifenesin and Pseudoephedrine HCl · PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1; GUAIFENESIN 380 mg/1; DEXTROMETHORPHAN HYDROBROMIDE 20 mg/1 · Tablet · Oral · Poly Pharmaceuticals, Inc.

NDC 50991-0214-01 · 100 TABLET in 1 BOTTLE · OTC MONOGRAPH DRUG · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $0.6289 per unit over the past year. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

Medicare Part D does not cover over-the-counter drugs — by law it pays only for products requiring a prescription.

How Part D pricing works →

NADAC price per unit

$0$0.25$0.5$0.75Feb 2016Sep 2025$0.6289
12 price points · per EA · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

#30 count
$18.87
#90 count
$56.60

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$19,541
1,330 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.0%chance of a new FDA shortage posting for dextromethorphan hbr, guaifenesin and pseudoephedrine hcl (oral solid) in the next 90 days

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
M012
TE code
Approval date
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Dextromethorphan HBr, Guaifenesin and Pseudoephedrine HCl (Tablet)

LabelerStrengthFirst seenLast seen
Poly Pharmaceuticals, Inc.PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1; GUAIFENESIN 380 mg/1; DEXTROMETHORPHAN HYDROBROMIDE 20 mg/1Aug 26, 2026Sep 2, 2026
Poly Pharmaceuticals, Inc.PSEUDOEPHEDRINE HYDROCHLORIDE 20 mg/1; GUAIFENESIN 380 mg/1; DEXTROMETHORPHAN HYDROBROMIDE 60 mg/1Jul 22, 2026Aug 19, 2026
Poly Pharmaceuticals, Inc.DEXTROMETHORPHAN HYDROBROMIDE 20 mg/1; GUAIFENESIN 380 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Poly-Vent DM — NDC 50991-0214-01," retrieved September 3, 2026, https://drugdashboards.com/drug/50991021401.

Free to cite with attribution — see how the data is put together.